OncoMatch/Clinical Trials/NCT06465433
Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
Is NCT06465433 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Tafasitamab for hematologic malignancies.
Treatment: Tafasitamab — This extension study is designed to enroll participants with hematologic malignancies who are receiving clinical benefit from tafasitamab treatment in a parent study with tafasitamab..
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Prior therapy
Must have received: tafasitamab (tafasitamab) — parent tafasitamab clinical study
Having been enrolled and is still receiving treatment with tafasitamab at the end of a parent tafasitamab clinical study
Cannot have received: tafasitamab (tafasitamab)
Has met one or more criteria for permanent tafasitamab treatment discontinuation as stipulated in the parent protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify